EE77 Cost-Effectiveness Analysis of Liraglutide for the Treatment of Obesity in Mexico

      In Mexico, obesity is the main public health concern and obesity-related conditions represent a very high costs for the Mexican public health system. Liraglutide 3mg is associated with significant and sustained weight loss and improves related complications. The objective of this study is to determine the cost-effectiveness of Liraglutide 3.0mg vs orlistat and no-treatment in Mexico.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Value in Health
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect